EXO Stock Analysis: Exor | AS

Asset Management | AS, Netherlands | Market Cap: 22.977m EUR | 12M Return: -7.1% | NL0012059018 | Charts, Fundamentals & Technical Analysis

Sports Automobiles, Commercial Trucks, Medical Imaging, Agricultural Machinery
Total Rating 20
Safety 30
Buy Signal -0.33
Asset Management
Industry Rotation: -6.1
Market Cap: 25.7B
Avg Turnover: 16.9M
Risk 3d forecast
Volatility20.8%
VaR 5th Pctl3.74%
VaR vs Median8.98%
Choppyness74.3%
Reward TTM
Sharpe Ratio-0.49
Rel. Str. IBD38.4
Rel. Str. Peer Group81.3
Character TTM
Beta0.633
Beta Downside0.692
Hurst Exponent0.499
Drawdowns 3y
Max DD39.28%
CAGR/Max DD-0.15
CAGR/Mean DD-0.34
EPS (Earnings per Share) EPS (Earnings per Share) of EXO over the last years for every Quarter: "2021-09": null, "2021-12": null, "2022-03": 1.32, "2022-06": 5.68, "2022-09": 0, "2022-12": null, "2023-03": 6.86, "2023-06": 0, "2023-09": 0, "2023-12": 16.1, "2024-03": 0, "2024-06": 0, "2024-09": 0, "2024-12": -0.11, "2025-06": -3.01, "2025-12": -15.2628, "2026-06": null,
Last SUE: -0.27
Qual. Beats: 0
Revenue Revenue of EXO over the last years for every Quarter: 2021-09: 8738.5, 2021-12: 17477, 2022-03: 9341.5, 2022-06: 18683, 2022-09: 11580.5, 2022-12: 23161, 2023-03: 10683.5, 2023-06: 21367, 2023-09: 11687.5, 2023-12: 23375, 2024-03: null, 2024-06: 15140, 2024-09: null, 2024-12: 255, 2025-06: -557, 2025-12: -3034, 2026-06: -1072,
Rev. CAGR: -84.85%
Rev. Trend: -93.0%
Qual. Beats: 0

Warnings

Choppy

Tailwinds

No distinct edge detected

Seasonality 4.1 years of data

Jan -2.7% 17
Feb +8.6% 53
Mar -9.1% 19
Apr +1.2% 14
May +1.6% 13
Jun +0.7% 13
Jul -1.1% 12
Aug +3.1% 24
Sep -2.9% 40
Oct -6.7% 18
Nov -2.6% 16
Dec -1.9% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: EXO Exor

Exor N.V. is a diversified Dutch-registered holding company controlled by the Agnelli family through its parent Giovanni Agnelli B.V. Founded in 1899 and headquartered in Amsterdam, the company holds significant stakes in a wide range of businesses across automotive, healthcare, agriculture and construction, commercial vehicles, sports, and media. Despite its broad portfolio, Exor is classified under the GICS Consumer Discretionary sector, with the Automobile Manufacturers sub-industry, reflecting the dominance of its automotive holdings in the groups overall valuation.

The companys automotive interests span luxury performance sports cars under Ferrari and mass-market vehicles under the Stellantis group, which includes brands such as Fiat, Alfa Romeo, Jeep, Maserati, Chrysler, Peugeot, Citroen, Opel, and Vauxhall. Its healthcare exposure comes through Philips, a major producer of diagnostic imaging, ultrasound, image-guided therapy, and personal health equipment. Exor also has a substantial position in agricultural and construction equipment, heavy and medium-duty trucks, powertrain technologies, and specialized vehicles used in defense, quarrying, and firefighting.

Beyond these core industrial holdings, Exors portfolio includes Juventus Football Club, a publishing business responsible for The Economist, luxury mens footwear and leather goods, oil and gas well services, clean energy solutions, and outpatient healthcare clinics. As a long-term investment holding company, Exors earnings are primarily driven by the operating performance of its portfolio companies rather than direct commercial activity, allowing it to deploy capital across cyclical and non-cyclical industries.

Headlines to Watch Out For
  • Ferrari shipments and mix shift boost segment margins
  • Stellantis earnings decline on weak European auto demand
  • CNH Industrial revenue falls with farm equipment cycle downturn
Piotroski VR-10 (Strict) 1.0
Net Income: -4.29b TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -5.79 > 1.0
NWC/Revenue: 202.3% < 20% (prev 44.55%; Δ 157.8% < -1%)
CFO/TA 0.01 > 3% & CFO 444.0m > Net Income -4.29b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 27.68 > 1.5 & < 3
Outstanding Shares: last quarter (202.4m) vs 12m ago -7.73% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 2.75% > 50% (prev 4.75%; Δ -2.00% > 0%)
Interest Coverage Ratio: -42.10 > 6 (EBIT TTM -4.21b / Interest Expense TTM 100.0m)
Altman Z'' 8.48
A: 0.06 (Total Current Assets 2.19b - Total Current Liabilities 79.0m) / Total Assets 35.8b
B: -0.03 (Retained Earnings -1.12b / Total Assets 35.8b)
C: -0.11 (EBIT TTM -4.21b / Avg Total Assets 37.9b)
D: 8.52 (Book Value of Equity 32.0b / Total Liabilities 3.76b)
Altman-Z'' = 8.48 = AAA
What is the price of EXO shares?

As of October 15, 2026, the stock is trading at EUR 69.20 with a total of 214,121 shares traded. Over the past week, the price has changed by -0.57%, over one month by -2.88%, over three months by +2.22% and over the past year by -7.12%.

Current recommended Stop Loss: 67.00 (which is 3.2% or 1.4 ATR below the current price).

Is EXO a buy, sell or hold?

Exor has no consensus analysts rating.

Exor (EXO) - Fundamental Data Overview as of 10 October 2026
Market Cap USD = 25.7b (23.0b EUR * 1.12012 EUR.USD)
P/S = 1.7692
P/B = 0.4603
Revenue TTM = 1.04b EUR
EBIT TTM = -4.21b EUR
EBITDA TTM = -3.69b EUR
Long Term Debt = 3.66b EUR (estimated: total debt 3.69b - short term 35.0m)
Short Term Debt = 35.0m EUR (from shortTermDebt, last quarter)
Debt = 3.69b EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.00m
Net Debt = 1.51b EUR (calculated: Debt 3.69b - CCE 2.18b)
Enterprise Value = 24.5b EUR (23.0b + Debt 3.69b - CCE 2.18b)
Interest Coverage Ratio = -42.10 (Ebit TTM -4.21b / Interest Expense TTM 100.0m)
EV/FCF = 55.16x (Enterprise Value 24.5b / FCF TTM 444.0m)
FCF Yield = 1.81% (FCF TTM 444.0m / Enterprise Value 24.5b)
FCF Margin = 42.61% (FCF TTM 444.0m / Revenue TTM 1.04b)
 Net Margin = -411.8% (Net Income TTM -4.29b / Revenue TTM 1.04b)
 Gross Margin = unknown ((Revenue TTM 1.04b - Cost of Revenue TTM 20.0m) / Revenue TTM)
 Tobins Q-Ratio = 0.68 (Enterprise Value 24.5b / Total Assets 35.8b)
Interest Expense / Debt = 2.71% (Interest Expense 100.0m / Debt 3.69b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -3.16b (EBIT -4.21b * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 27.68 (Total Current Assets 2.19b / Total Current Liabilities 79.0m)
Debt / Equity = 0.12 (Debt 3.69b / totalStockholderEquity, last quarter 32.0b)
 Debt / EBITDA = -0.41 (negative EBITDA) (Net Debt 1.51b / EBITDA -3.69b)
 Debt / FCF = 3.41 (Net Debt 1.51b / FCF TTM 444.0m)
Total Stockholder Equity = 34.2b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.33% (Net Income -4.29b / Total Assets 35.8b)
RoE = -12.53% (Net Income TTM -4.29b / Total Stockholder Equity 34.2b)
RoCE = -11.11% (EBIT -4.21b / Capital Employed (Equity 34.2b + L.T.Debt 3.66b))
 RoIC = -8.85% (negative operating profit) (NOPAT -3.16b / Invested Capital 35.7b)
 WACC = 7.35% (E(23.0b)/V(26.7b) * Re(8.21%) + D(3.69b)/V(26.7b) * Rd(2.71%) * (1-Tc(0.25)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.31 | Cagr: -6.36%
[DCF] Terminal Value 73.10% ; FCFF base≈1.39b ; Y1≈1.22b ; Y5≈985.7m
[DCF] Fair Price = 70.57 (EV 15.8b - Net Debt 1.51b = Equity 14.3b / Shares 202.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.27 | # QB: 0
Revenue Correlation: -93.05 | Revenue CAGR: -84.85% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.27 | Chg30d=-42.50% | Revisions=+25% | GrowthEPS=-48.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=1.28 | Chg30d=+0.98% | Revisions=+25% | GrowthEPS=+0.4% | GrowthRev=+0.0%